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Introduction {#sec1}
============

The second messenger 3′,5′-cyclic adenosine monophosphate (cAMP) is a potent driver of cellular responses to hormonal and environmental cues ([@bib43]). cAMP mediates the activation of the protein kinase A (PKA) holoenzyme ([@bib67]), which subsequently phosphorylates cellular substrates ([@bib60]). The transcriptional response to cAMP proceeds via the PKA-mediated phosphorylation of cAMP response element (CRE)-binding protein (CREB) family members (CREB1, ATF1, and CREM) ([@bib41]). Phosphorylation of CREB at S133 induces a conformational change that enables the association of CREB with the histone acetyltransferases CREB-binding protein (CBP) and p300 ([@bib48]). In parallel, cAMP also stimulates the association of CREB with the family of cAMP-regulated transcriptional coactivators (CRTCs, CRTC1--3) over relevant genomic CREB-binding sites (CRE sites) ([@bib2]).

Under basal conditions 5′ AMP-activated protein kinase family members, most notably the salt-inducible kinases (SIKs, SIK1--3), sequester the three CRTCs in the cytoplasm by phosphorylation at conserved sites, which promotes phosphorylation-dependent 14-3-3 protein binding ([@bib63], [@bib71]). cAMP stimulation triggers the PKA-mediated phosphorylation and inhibition of SIK1--3 ([@bib64]), leading to the dephosphorylation of CRTCs, which shuttle to the nucleus and drive cAMP/CREB target gene expression ([@bib71]).

In addition to their regulation by SIKs, CRTCs are also controlled by calcium signaling via the Ca^2+^/calmodulin-dependent protein phosphatase calcineurin (CaN) ([@bib51]), which binds to and dephosphorylates the CRTCs at 14-3-3 binding sites ([@bib2]). The most abundant cellular phosphatases protein phosphatase 1 (PP1) and PP2A also appear to stimulate the dephosphorylation of CRTC2 ([@bib61], [@bib70]), although the context in which these ubiquitous enzymes regulate CRTC activities is unclear.

Multiple CRTC family members are co-expressed in mammalian tissues: CRTC1 and CRTC2 are produced in the brain ([@bib1], [@bib28]) and pancreatic islets ([@bib16], [@bib39]), for example, whereas CRTC2 and CRTC3 are found in fat ([@bib22], [@bib62]), liver ([@bib33], [@bib50]), and bone marrow-derived immune cells ([@bib31], [@bib38]). Nevertheless, individual CRTCs appear to execute dominant roles in certain tissues, with CRTC1 controlling memory ([@bib45]) and behavior ([@bib5]), entraining the circadian clock ([@bib27]), and promoting energy expenditure ([@bib1]). By contrast, CRTC2 regulates liver gluconeogenesis ([@bib33]) and beta-cell viability ([@bib4], [@bib16]), whereas CRTC3 promotes adipose tissue ([@bib62]) and anti-inflammatory macrophage function ([@bib38]). However, it is unknown whether these differences reflect the relative abundance or distinct activation properties of CRTC family members in relevant tissues.

Based on the importance of CRTC dephosphorylation for transcriptional activation, we systematically examined the relative association of individual CRTC family members across the mammalian complement of Ser/Thr-specific protein phosphatases by mass spectrometry. We identified selective interactions of CRTC1/2 with CaN and uncovered an unexpected role for PP2A in binding to and activating CRTC3 in response to extracellular signals. These results point to a novel role for PP2A in mediating effects of growth factor cues on the selective activation of a distinct CRTC family member.

Results {#sec2}
=======

Selective Binding of Ser/Thr-Specific Protein Phosphatases to CRTC Family Members {#sec2.1}
---------------------------------------------------------------------------------

Although they are all regulated by cAMP and the SIKs, individual CRTC family members can perform unique roles ([Figures 1](#fig1){ref-type="fig"}A and 1B). We hypothesized that these distinct phenotypes reflect in part differences in protein-protein interactions, rather than differences in CRTC protein abundance. In previous immunoprecipitation (IP)-mass spectrometry (MS) studies, we identified two conserved SIK/14-3-3-binding sites that inhibit CRTC activity ([@bib63]) (S171 and S275 in CRTC2; [Figure 1](#fig1){ref-type="fig"}C). Using the corresponding HEK 293T cell dataset to identify Ser/Thr phosphatases that interact with overexpressed CRTC1--3 ([Figures 2](#fig2){ref-type="fig"}A and 2B), we detected the regulatory and catalytic subunits of CaN in IPs of CRTC1 and CRTC2, but not CRTC3 ([Figures 2](#fig2){ref-type="fig"}C and 2D). Conversely, CRTC3 but not CRTC1/2 associated very strongly with PP2A holoenzymes; spectral counts for catalytic (PPP2CA/B), scaffold (PPP2R1A/B), and 55-kDa regulatory B (B55, PPP2R2A--D) subunits were more than 10-fold enriched in IPs of CRTC3 relative to CRTC1/2. Other phosphatases (PP1, PP4, and PP6) appeared to associate comparably, albeit weakly with all CRTC family members ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1Common Regulation and Unique Functions of the CRTC Family(A) Upon activation of G protein-coupled receptors (GPCRs), cells generate the second messenger cAMP via adenylyl cyclases (ACs). cAMP induces PKA activity, which upon phosphorylation activates CREB and inactivates the SIKs. Correspondingly, CRTCs are dephosphorylated by the phosphatases PP1 and PP2A and the calcium-responsive CaN, leading to the loss of 14-3-3 protein binding and nuclear translocation. Inside the nucleus, CRTCs bind to CREB over relevant genomic cAMP response element (CRE)-binding sites and drive transcription.(B) Table lists unique roles of individual CRTC family members.(C) To-scale representation of the cAMP-regulated transcriptional coactivator (CRTC) protein family (according to *Mus musculus* CRTC proteins). All CRTCs contain multiple salt-inducible kinase (SIK) phosphorylation sites that mediate cytoplasmic sequestration upon 14-3-3 protein binding (black and gray). Two of these sites are conserved and function cooperatively in all CRTCs (gray: S171 and S275 in CRTC2; CBD, CREB-binding domain; TA, transactivation domain).Figure 2CRTC Family Members Are Regulated by Distinct Ser/Thr Protein Phosphatases(A) Overexpressed N- and C-terminally FLAG-tagged CRTC1--3 were subjected to the immunoprecipitation and mass spectrometry (IP-MS) protocol following exposure to 10 μM forskolin (Fsk) for 1 hr.(B) Coomassie brilliant blue (CBB)-stained SDS-PAGE of coIP from C-terminally FLAG-tagged CRTC1--3 subjected to MS (\*, heat shock proteins).(C) Tables showing recovery of individual subunits from the Ser/Thr phosphatases calcineurin (CaN) and protein phosphatase 2 (PP2A; comparison N-terminally tagged CRTC1--3; SPCs, spectral counts).(D) Western blot analysis of the MS coIP of N- and C-terminally FLAG-tagged CRTC1--3 with endogenous 14-3-3 proteins, CaN, and PP2A (Ab, Abcam; CST, Cell Signaling Technology).(E) Western blot analysis of the coIP of FLAG-tagged CRTC2 and CRTC3 with endogenous 14-3-3 proteins, CaN, and PP2A. One hour before coIP, cells were treated with 10 μM Fsk and 100 nM cyclosporin (CsA). CRTC2 and CRTC3 were expressed from a plasmid containing the constitutive ubiquitin C promoter (UbC), which drives the expression of EGFP via an internal ribosome entry site. In HEK 293T cells the P-CREB S133 antibody recognizes two bands; the upper band corresponds to CREB1 and the lower band to ATF1 (calculated molecular weight: ∼ 37 and 29 kDa).(F) Western blot analysis of the coIP of FLAG-tagged CRTC3 14-3-3 binding site mutants with endogenous 14-3-3s and PP2A.

We confirmed the mutually exclusive interactions of CRTC2 with CaN and CRTC3 with PP2A by co-immunoprecipitation (coIP) ([Figure 2](#fig2){ref-type="fig"}F). Exposure to the adenylyl cyclase activator forskolin (Fsk) triggered the dephosphorylation of both CRTC2 and CRTC3 at SIK/14-3-3 sites (CRTC2/3: S171/S162 and S275/S273), thereby decreasing their association with 14-3-3 proteins. Co-treatment with the CaN inhibitor cyclosporin (CsA) ([@bib29]) selectively impaired the Fsk-mediated dephosphorylation of CRTC2 at S171, leading to increases in 14-3-3 binding. Fsk stimulation decreased the association of CRTC2 with CaN, but it had no effect on the association of CRTC3 with PP2A. We considered that CRTC3 phosphorylation at 14-3-3 binding sites may modulate PP2A interaction ([Figure 2](#fig2){ref-type="fig"}G). Although it eliminated 14-3-3 binding, mutation of all five SIK/14-3-3 sites ([@bib63]) in CRTC3 had no effect on its association with PP2A. Collectively, these results indicate that the interaction of CRTC3 with the B55 PP2A holoenzyme is independent of SIK-mediated phosphorylation.

Identification of a Conserved PP2A-Binding Region in CRTC3 {#sec2.2}
----------------------------------------------------------

To characterize the PP2A-binding region (PBR) in CRTC3, we generated serial N- and C-terminal truncations of CRTC3 and analyzed these for PP2A association by coIP ([Figure S2](#mmc1){ref-type="supplementary-material"}). This analysis uncovered a 20-amino acid core PBR (amino acids 380--401) located within the central regulatory domain of CRTC3 ([Figures 3](#fig3){ref-type="fig"}A and 3B). Pointing to an important function for this region, the PBR amino acid sequence is identical between humans and mice ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Characterization of the PP2A-Binding Region (PBR) in CRTC3(A) Western blot analysis showing recovery of endogenous PP2A from IPs of FLAG-tagged CRTC3 mutants. The only fragment that abolished PP2A binding is highlighted in red (201--383).(B) To-scale representation of CRTC3 protein fragments assayed for interaction with PP2A. In orange the PBR of CRTC3 (*Mus musculus* amino acids 380--401).(C) CRTC3 sequence alignment of the PBR from multiple vertebrate species (CRTC3 sequences were obtained via UniProt; [@bib68]).(D) Sequence alignment of the PBR from vertebrate CRTC3 proteins compared with *M. musculus* CRTC2 425--444 (in purple).(E and F) (E) To-scale representation of the CRTC2 (light green) and CRTC3 (dark green) hybrid proteins assayed for PP2A binding. Hybrid proteins: CRTC2 H1 \[mCRTC2(328--421) replaced with mCRTC3(326--379), in blue\], CRTC2 H2 \[mCRTC2(328--449) replaced with mCRTC3(326--402)\], and CRTC3 H1 \[mCRTC3(322--407) replaced with mCRTC2(324--454)\]. (F) Western blot showing recovery of endogenous PP2A from IPs of FLAG-tagged CRTC2/3 mutants.

Although CRTC2 does not bind PP2A, it contains a PBR-related sequence at 425--444 ([Figure 3](#fig3){ref-type="fig"}D). We generated CRTC2/3 hybrids to test whether sequences flanking this core region modulate the PP2A association ([Figures 3](#fig3){ref-type="fig"}E and 3F). Similar to the PP2A interaction patterns of truncated CRTC3 protein fragments, insertion of mCRTC3 326--402 promoted binding of CRTC2 to PP2A (CRTC2 H2), whereas insertion of the corresponding region of CRTC2 (mCRTC2 324--454) into CRTC3 (CRTC3 H1) abolished PP2A binding. However, insertion of CRTC3 sequences flanking the PBR into CRTC2 (mCRTC3 326--379; CRTC2 H1) increased PP2A binding to a level that was intermediate between CRTC2 and CRTC3. These findings indicate that although mCRTC3 380--401 is absolutely required for the strong interaction with PP2A, regions outside the PBR also contribute to complex formation.

Phosphorylation of the PBR Increases PP2A Binding {#sec2.3}
-------------------------------------------------

The CRTC3 PBR contains three conserved Ser/Thr residues that appear to undergo phosphorylation ([@bib26]) ([Figure 4](#fig4){ref-type="fig"}A). We confirmed the phosphorylation of CRTC3 at S391 and S396 by MS analysis ([Figure S3](#mmc1){ref-type="supplementary-material"}). To assess the potential effects of these modifications within the PBR on the CRTC3-PP2A interaction, we performed mutagenesis studies ([Figure 4](#fig4){ref-type="fig"}B). Although alanine substitutions at T394 and S396 had no effect on PP2A binding, mutation of either S391 or the flanking P392 to alanine abolished this interaction. To monitor phosphorylation at the critical S391 site, we generated a phospho-specific antiserum (P-CRTC3 S391). Western blot analysis revealed robust S391 phosphorylation following overexpression of CRTC3 wild-type (WT) and T394A or S396A mutant proteins in HEK 293T cells.Figure 4Phosphorylation of CRTC3 at S391 Promotes PP2A Association and CRTC3 Activation(A) Primary sequence of the PP2A-binding region (PBR) in CRTC3 (*H. sapiens* and *Mus musculus* numbering is identical). Phosphorylated residues in red ([@bib26]).(B) Western blot analysis showing recovery of endogenous PP2A from IPs of FLAG-tagged CRTC3 mutants.(C) Western blot analysis of endogenous PP2A and 14-3-3s recovered from IPs of FLAG-tagged CRTC3 S391 mutants.(D--F) (D) EVX-Luc reporter assay measuring the effect of overexpressed CRTC3 wild-type (WT) and S391A mutant upon CREB-dependent gene expression. EVX-Luc activity was measured after 4 hr of DMSO/Fsk treatment (10 μM) (n = 15, ±SEM; \*\*\*\*p \< 0.0001). (E) Immunofluorescence of HEK 293T cells transfected with FLAG-tagged CRTC3 WT and S391A. Cells were stained for FLAG epitope, PPP2R1A, and counterstained with DAPI. (Orange arrows depict cells in mitosis; scale bar, 20 μm.) (F) Graph depicting the relative subcellular localization of CRTC3 WT and S391 mutant (predominantly cytoplasmic \[N \< C\], comparable \[N=C\], and predominantly nuclear distribution \[N \> C\]).

To determine the importance of S391 phosphorylation for the CRTC3-PP2A interaction, we tested whether substitution of this phosphoacceptor with alanine or a phosphomimetic (Glu) alters complex formation ([Figure 4](#fig4){ref-type="fig"}C). In contrast to WT CRTC3, neither S391A nor S391E mutant CRTC3 protein associated detectably with PP2A. Correspondingly, phospho-S391-defective CRTC3 proteins were phosphorylated to a greater extent at 14-3-3 binding sites (P-CRTC3 S273), and as a result, the association of S391A/E mutants with 14-3-3 proteins was stronger compared with WT.

In a transient CRE luciferase-based assay for the quantification of cAMP-dependent gene expression ([@bib12]), the phosphorylation-defective S391A mutant CRTC3 exhibited ∼2-fold lower basal transcriptional activity compared with WT CRTC3 ([Figure 4](#fig4){ref-type="fig"}D). WT and S391A CRTC3 CRE activities were more similar following exposure to Fsk, however, suggesting that S391 modulates CRTC3 activity in a cAMP-independent manner. We performed immunofluorescence studies to determine the subcellular localization of the S391A mutant ([Figures 4](#fig4){ref-type="fig"}E and 4F). In contrast to the predominantly nuclear WT CRTC3, S391A mutant protein was primarily localized in the cytoplasm under basal conditions. In keeping with its effects on CRE reporter activity, Fsk promoted the nuclear translocation of CRTC3 WT and S391A comparably ([Figure S4](#mmc1){ref-type="supplementary-material"}).

PP2A has multifaceted roles in the cell cycle and is thought to function as a tumor suppressor ([@bib20], [@bib72]). Various cellular proteins can inhibit PP2A activity, including the phosphorylation-dependent regulators of mitosis ENSA, ARPP19, and Bod1 ([@bib19], [@bib52]). In contrast to CRTC3 ([@bib62]), these proteins are small (12--20 kDa) ([@bib68]) and knockdown or overexpression of any one regulator typically leads to growth arrest and embryonic lethality ([@bib15], [@bib40]). Arguing against a role for CRTC3 as a PP2A inhibitor, cellular PP2A activity and proliferation appeared comparable between cells expressing WT or phosphorylation-defective (S391A) CRTC3 in HEK 293T cells ([Figure S5](#mmc1){ref-type="supplementary-material"}). These results support the notion that S391 phosphorylation selectively increases CRTC3 activity by promoting its association with the PP2A holoenzyme, which in turn dephosphorylates CRTC3 at remote SIK/14-3-3 sites, leading to CRTC3 nuclear translocation and CREB target gene activation.

MAPKs and CDKs Promote PBR Phosphorylation at S391 {#sec2.4}
--------------------------------------------------

Realizing that S391 phosphorylation of CRTC3 increases its interaction with PP2A, we set out to identify relevant protein kinases that mediate the phosphorylation of this site. Based on the importance of a flanking proline at the +1 position relative to S391, we addressed the potential involvement of proline-directed kinases in this process by pharmacological inhibition ([Figure 5](#fig5){ref-type="fig"}A). Exposure to the cyclin-dependent kinase (CDK1/2/5) inhibitor roscovitine (IC~50~: CDK1/2/5 = 0.2--0.8 μM, ERK1/2 = 15--30 μM) ([@bib42]) and the ERK1/2 inhibitor SCH772984 (IC~50~: ERK1/2 = 0.004/0.001 μM) ([@bib44]) reduced both CRTC3 S391 phosphorylation and PP2A binding following CRTC3 overexpression in HEK 293T cells. CDKs ([@bib25]) and mitogen-activated protein kinases (MAPKs) such as ERK1/2 ([@bib6]) are proline-directed Ser/Thr kinases that appear capable of phosphorylating CRTC3 at S391. The CK1α/δ inhibitor longdaysin (IC~50~: CK1α/δ = 6--9 μM, ERK2 = 52 μM) ([@bib24]) also inhibited S391 phosphorylation, with the PBR (S~391~PLT~394~) containing a casein kinase 1 (CK1) consensus motif pS/Txx(x)[S/T]{.ul} (underlined = CK1 phosphorylated residue) ([@bib32]). In contrast to its effects on WT CRTC3, longdaysin did not impair PP2A binding in the context of the T394A mutant ([Figure S6](#mmc1){ref-type="supplementary-material"}), indicating that S391 and T394 phosphorylation are required for full binding of PP2A in cells overexpressing WT CRTC3.Figure 5MAPKs and CDKs Promote S391 Phosphorylation and Activation of CRTC3(A) Western blot analysis of endogenous PP2A recovered from IPs of FLAG-tagged CRTC3. Four hours before the IP, HEK 293T cells were treated with small molecule kinase inhibitors: 20 μM longdaysin (IC~50~: CK1α/δ = 6--9 μM, ERK2 = 52 μM) ([@bib24]), 1 μM palbociclib (IC~50~: CDK4/6 = 0.009--0.015 μM) ([@bib18]), 20 μM roscovitine (IC~50~: CDK1/2/5 = 0.2--0.8 μM, ERK1/2 = 15--30 μM) ([@bib42]), 100 nM dinaciclib (IC~50~: CDK1/2/5 = 0.001--0.003 μM) ([@bib49]), and 100 nM SCH772984 (IC~50~: ERK1/2 = 0.004/0.001 μM) ([@bib44]).(B) Western blot analysis showing the effects of 21-hr exposure to nocodazole (noc, 0.1 μg/mL) on S391 phosphorylation of endogenous CRTC3. Four hours before cell lysis, HEK 293T cells were treated with roscovitine (20 μM) and dinaciclib (200 nM). In HEK 293T cells the P-CRTC3 S273 antibody recognizes two bands, the upper band being CRTC2 and the lower band CRTC3 (calculated molecular weight: ∼ 73 and 67 kDa).(C) Western blot analysis showing the effects of 1-hr TPA (200 nM) and Fsk (10 μM) treatment on S391 phosphorylation of endogenous CRTC3. In addition, HEK 293T cells were (co-)treated with SCH772984 (SCH; 100 nM) for the indicated time before cell lysis.(D) Western blot analysis of the coIP of endogenous CRTC3 with 14-3-3 proteins by using the hCRTC3(414-432) antibody. Before the IP, HEK 293T cells were (co-)treated with TPA (200 nM, 1 hr) and SCH772984 (SCH; 200 nM, 2 hr).(E) Immunofluorescence of HEK 293T cells following 30 minutes of DMSO and TPA (200 nM) stimulation. Cells were stained for endogenous CRTC3 with the hCRTC3(414--432) antibody and counterstained with DAPI (scale bar, 20 μm).

To evaluate the potential role of CDKs in modulating endogenous CRTC3 S391 phosphorylation, we arrested HEK 293T cells in the G2/M phase with nocodazole ([Figure 5](#fig5){ref-type="fig"}B). Although undetectable in the basal state, phosphorylations of CRTC3 at S391 and nucleophosmin (NPM) at T199, a known CDK target ([@bib69]), were both upregulated following nocodazole arrest. Consistent with these effects, short-term CDK inhibition with roscovitine and dinaciclib (IC~50~: CDK1/2/5 = 0.001--0.003 μM) ([@bib49]) blocked the phosphorylation of both proteins.

To test the effect of ERK and cAMP signaling on endogenous S391 phosphorylation of CRTC3, we stimulated HEK 293T cells with either 12-O-tetradecanoylphorbol-13-acetate (TPA) ([@bib58]) or Fsk ([Figure 5](#fig5){ref-type="fig"}C). In contrast to Fsk, which promoted the dephosphorylation of CRTC2 and CRTC3 at 14-3-3 sites (P-CRTC3 S273: top CRTC2 and bottom CRTC3), exposure to TPA upregulated ERK activity (P-ERK T202 Y204) and induced CRTC3 phosphorylation at S391. These effects were suppressed by pretreatment with the ERK1/2 inhibitor SCH772984.

Following exposure to TPA or nocodazole, we detected two immunoreactive bands using the S391 phospho-specific antiserum. Both bands correspond to endogenous CRTC3, as revealed in knockdown studies using CRTC3-specific short hairpin RNA (shRNAs) ([Figure S7](#mmc1){ref-type="supplementary-material"}). In previous studies with HEK 293T cells, we found that TPA does not activate the predominant CRTC family member CRTC2 ([@bib54]). By contrast, exposure to TPA decreased 14-3-3 protein binding to CRTC3, thereby enhancing its nuclear localization ([Figures 5](#fig5){ref-type="fig"}D and 5E). Taken together, these results indicate that MAPKs and CDKs both regulate the S391 phosphorylation and activation of endogenous CRTC3.

PBR Phosphorylation Increases CRTC3 Activity {#sec2.5}
--------------------------------------------

Based on the importance of CRTC3 for adipose function ([@bib62], [@bib74]), we examined CRTC3 S391 phosphorylation in brown-adipose-tissue-derived stromal vascular fraction (bSVF) cells, which are enriched in preadipocytes ([@bib21]) ([Figure 6](#fig6){ref-type="fig"}A). In the basal state, S391-phosphorylated CRTC3 was detected in WT, but not in CRTC3 knockout (KO) bSVFs. Having seen their effects on CRTC3 S391 phosphorylation in HEK 293T cells, we tested CDK and ERK inhibitors in bSVFs ([Figure 6](#fig6){ref-type="fig"}B). Although both roscovitine and dinaciclib inhibited CDK activity as revealed by the corresponding reduction in NPM T199 phosphorylation, the ERK1/2 inhibitor SCH772984 was most effective in reducing CRTC3 S391 phosphorylation. We evaluated the importance of ERK signaling for CREB target gene expression by exposing bSVFs to SCH772984 ([Figure 6](#fig6){ref-type="fig"}C). SCH772984 treatment partially blocked the Fsk-mediated induction of canonical CREB target genes *NR4A1* and regulator of G-protein signaling-2 (*RGS2*) ([@bib54], [@bib62]). The inhibitory effects of SCH772984 appear to be CRTC3 dependent, because they were absent in CRTC3 KO bSVFs. Taken together, these results demonstrate that in bSVFs ERK activity functions cooperatively with cAMP/PKA signals to promote CREB target gene expression through its effects on CRTC3.Figure 6ERK-Mediated Activation of CRTC3 in Undifferentiated bSVFs(A) Western blot analysis of primary brown adipose stromal vascular fraction (bSVF) cells generated from wild-type C57BL/6 (WT) and CRTC3 knockout mice (KO).(B) Western blot analysis showing the effects of 4-hr treatment with roscovitine (20 μM), dinaciclib (200 nM), and SCH772984 (200 nM) on phospho-S391 CRTC3 levels in bSVF WT and KO cells.(C) *NR4A1* and *RGS2* mRNA levels of bSVF CRTC3 WT and KO cells following (co-)treatment with SCH772984 (SCH; 200 nM, 4 hr) and Fsk (10 μM, 1 hr). Values represent data from three independent experiments normalized to *RPL32* and relative to CRTC3 WT DMSO. (*n* = 3, ±SD; ns, not statistically significant, \*\*p \< 0.01)

Discussion {#sec3}
==========

The second messenger cAMP promotes cellular gene expression via the PKA-mediated phosphorylation and inhibition of the SIKs, leading to CRTC nuclear translocation upon dephosphorylation and release from 14-3-3 proteins ([Figure 7](#fig7){ref-type="fig"}A). Here we show that the association of CRTC members with different protein phosphatases provides distinct stimulus-dependent mechanisms for the induction of CREB target genes ([Figures 7](#fig7){ref-type="fig"}B and 7C).Figure 7Differential Regulation of CRTC Family Members by Calcineurin and B55 PP2A(A) Scheme depicting the cAMP-dependent regulation of CRTC1--3. In the basal state, SIK-mediated phosphorylation sequesters the CRTCs in the cytoplasm by inducing 14-3-3 interactions. Upon cAMP stimulation, PKA-mediated phosphorylation inactivates the SIKs. CRTCs are dephosphorylated by protein phosphatases (PPs), lose 14-3-3 binding, and translocate to the nucleus.(B) Scheme depicting the regulation of CRTC1 and CRTC2 by calcineurin. Upon Ca^2+^ stimulation, increased calcineurin activity dephosphorylates 14-3-3 binding sites, leading to nuclear translocation of CRTC1/2.(C) Scheme depicting the regulation of CRTC3 by PP2A. Phosphorylation by MAPKs or CDKs at S391 within the PBR (amino acids 380--401) of CRTC3 enables B55 PP2A holoenzyme recruitment and subsequent dephosphorylation of CRTC3 at 14-3-3 binding sites.

The calcium-responsive phosphatase CaN interacts with substrates that contain PxIxIT motifs ([@bib36]), including vertebrate CRTC1 and CRTC2, but not CRTC3 (mCRTC1: [P]{.ul}~219~G[I]{.ul}N[I]{.ul}F, [P]{.ul}~555~N[I]{.ul}IL[T]{.ul} and mCRTC2: [P]{.ul}~249~G[I]{.ul}N[I]{.ul}F, [P]{.ul}~614~N[I]{.ul}IL[T]{.ul}). Although PxIxIT motifs regulate the substrate affinity of CaN ([@bib37], [@bib57]), its phosphatase activity is dependent upon Ca^2+^/calmodulin ([@bib51]). As a result, the Ca^2+^/CaN -dependent regulation is limited to CRTC1 and CRTC2 ([@bib1], [@bib34], [@bib59], [@bib3], [@bib8]).

By contrast, CRTC3 binds to the B55 PP2A holoenzyme following phosphorylation of CRTC3 at S391 by MAPK/CDKs. Within the PBR (mCRTC3 PBR: 380--401) the S391 phosphorylation site (PVS~391~P) forms part of an optimal ERK1/2 motif (Px\[S/T\]P) ([@bib6]). The PBR also contains an MAPK docking motif (D domain), with characteristic basic and alternating hydrophobic residues ([RRR]{.ul}QPP[V]{.ul}S~391~P[L]{.ul}T[L]{.ul}) ([@bib55]). Stimuli that upregulate ERK activity (epidermal growth factor and angiotensin II), also promote the phosphorylation of CRTC3 at S391/S396 ([@bib46], [@bib9]). Superimposed on effects of ERKs, CDKs also appear to phosphorylate CRTC3 at S391 in growth-arrested cells ([@bib47], [@bib17]). Indeed, CRTC3 was also identified in a study of mitotic phosphorylation substrates within the chromosomal passenger complex ([@bib73]), which controls cell division together with the CDKs ([@bib7]). Consistent with the importance of PP2A-mediated activation of CRTC3, in primary calvarial osteoblasts the parathyroid-hormone-induced nuclear translocation of CRTCs was blocked by the PP2A/PP1 inhibitor okadaic acid in case of CRTC3, but not for CRTC2 ([@bib56]).

Although the regulatory subunits of PP2A appear important in distinguishing between different substrates, relevant substrate recognition motifs for the PP2A holoenzyme have not been reported until recently ([@bib20], [@bib72]). The B55 PP2A holoenzyme has been found to recognize substrates containing a CDK1 phosphorylation site flanked on both sides by a polybasic region ([@bib13]); a short LxxIxE motif appears to mediate interaction with the B56 PP2A holoenzyme ([@bib23]). The PBR of CRTC3 includes an N-terminal Arg triplet but lacks any basic C-terminal sequences (mCRTC3: [RRR]{.ul}QPPVS~391~PLTLSPGPE). Only B55 PP2A subunits were recovered from IPs of all CRTCs, which contain a common sequence inside their PBR-related region consisting of two hydrophobic residues flanking an SP motif (mCRTC1/2/3: P[L]{.ul}S~332~P[I]{.ul}TQ/P[L]{.ul}S~434~P[L]{.ul}SL/P[V]{.ul}S~391~P[L]{.ul}TL). Although it lacks an essential glutamate at position 6, this common PBR-like motif in CRTC family members bears more similarity with the LxxIxE motif described for the B56 PP2A holoenzyme. Similar to our findings, phosphorylation of residues within the LxxIxE motif also increases B56 PP2A affinity, leading to the dephosphorylation of distal residues in relevant substrates such as Repo-Man (L[S]{.ul}PIPE), BubR1 (L[S]{.ul}PIIE), and RacGAP1 (L[S]{.ul}TIDE; underlined = phosphorylated residues) ([@bib23], [@bib53], [@bib35]). Future biochemical studies should reveal the extent to which the PBR we identified represents a distinct binding motif for the B55 PP2A holoenzyme.

The second messenger cAMP is traditionally thought to inhibit cell division, but in a subset of tissues, cAMP appears to cooperate with MAPK/ERK signals in promoting proliferation and differentiation ([@bib14]). This cross talk is noteworthy in adipose tissue wherein β-adrenergic signaling triggers the activation of both cAMP and MAPK signaling pathways ([@bib11]), often in combination with growth factors such as insulin/insulin growth factor-1 ([@bib30], [@bib66]). As loss of CRTC3 expression increases brown adipocyte proliferation and differentiation and protects against high-fat-diet-induced adipose expansion ([@bib62], [@bib74]), future studies should address the specific roles of S391 phosphorylation in this context. This cooperative effect of cAMP and MAPK signals on CRTC3 activity has also been reported in regulatory macrophages where lipopolysaccharides (LPS) and prostaglandin E2 (PGE2) promote expression of the anti-inflammatory interleukin 10 ([@bib10], [@bib38]). Based on the ability of PGE2 to stimulate the cAMP pathway and LPS to activate multiple MAPK family members ([@bib65]), our results suggest that these CRTC3-specific effects proceed via the recruitment of B55 PP2A.

Limitations of the Study {#sec3.1}
------------------------

We used HEK 293T cells to characterize CRTC3-PP2A complex formation and its regulation by MAPK- and CDK-mediated phosphorylation. Although this approach was valuable in characterizing these molecular components and their downstream effects on CRTC3 activation, the relevant extracellular signals that act upstream to trigger the interaction of CRTC3 with PP2A remain relatively unknown. Our studies with brown pre-adipocytes support a potential role for ERK in mediating effects of β-adrenergic signals on recruitment of PP2A and on the subsequent activation of CRTC3. Future studies with phospho (S391)-specific antiserum should reveal the physiological contexts in which this site is phosphorylated, and mutant mice expressing phospho-S391 defective CRTC3 should provide insight into the physiological importance of this modification.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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